Singapore markets close in 1 hour 44 minutes

BioCryst Pharmaceuticals, Inc. (BCRX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
15.48-0.67 (-4.15%)
At close: 04:00PM EST
15.58 +0.10 (+0.65%)
After hours: 07:51PM EST
Currency in USD

Valuation measures4

Market cap (intra-day) 2.10B
Enterprise value 2.07B
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/sales (ttm)18.17
Price/book (mrq)56.59
Enterprise value/revenue 18.11
Enterprise value/EBITDA -11.48

Trading information

Stock price history

Beta (5Y monthly) 2.48
52-week change 370.67%
S&P500 52-week change 322.74%
52-week high 318.48
52-week low 38.37
50-day moving average 312.82
200-day moving average 314.23

Share statistics

Avg vol (3-month) 33.53M
Avg vol (10-day) 37.21M
Shares outstanding 5179.94M
Implied shares outstanding 6N/A
Float 8165.65M
% held by insiders 11.14%
% held by institutions 159.28%
Shares short (30 Dec 2021) 426.08M
Short ratio (30 Dec 2021) 410.15
Short % of float (30 Dec 2021) 416.28%
Short % of shares outstanding (30 Dec 2021) 414.49%
Shares short (prior month 29 Nov 2021) 424.18M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2020
Most-recent quarter (mrq)29 Sep 2021

Profitability

Profit margin -198.88%
Operating margin (ttm)-160.46%

Management effectiveness

Return on assets (ttm)-51.75%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)114.03M
Revenue per share (ttm)0.64
Quarterly revenue growth (yoy)571.80%
Gross profit (ttm)-106.83M
EBITDA -182.19M
Net income avi to common (ttm)-226.78M
Diluted EPS (ttm)-1.27
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)199.6M
Total cash per share (mrq)1.11
Total debt (mrq)310.65M
Total debt/equity (mrq)N/A
Current ratio (mrq)1.89
Book value per share (mrq)-0.82

Cash flow statement

Operating cash flow (ttm)-154.34M
Levered free cash flow (ttm)-103.06M